A ctivation of the renin angiotensin system (RAS) is involved in the pathogenesis of several cardiovascular diseases, including atherosclerosis and hypertension. 1 The classical view of atherosclerosis as a lesion composed by lipid deposits has now been changed to a chronic inflammatory disorder, regulated by the production of inflammatory mediators and immune cells, which are involved in the initiation, progression, and rupture of the plaque. 2 The inflammatory response includes endothelial dysfunction, increased adhesion molecule expression, and release of proinflammatory mediators (chemokines and cytokines). Inflammatory mechanisms have also recently been related to development of hypertension-induced vascular damage. 1, 3 The nuclear factor-B (NF-B) is a pivotal transcription factor in inflammatory diseases and chronic immune responses. 4 Many stimuli relevant to cardiovascular diseases, including cytokines (IL-6 and TNF-␣), growth factors, Angiotensin II (Ang II), signals elicited by ischemic stress (NO and oxygen free radicals), and mechanical forces, have been shown to activate NF-B. This transcription factor participates in vascular damage through the regulation of several genes, including adhesion molecules, cytokines, chemokines, angiotensinogen, and other products involved in proliferation and immune responses. 4 In pathological conditions, elevated tissue NF-B activity correlated with inflammatory events has been observed. 1, 3 NF-B inhibition suppresses the development of atherosclerotic lesions by preventing inflammation, vascular smooth muscle cell (VSMC) proliferation, and apoptosis. 4 -7 Blockade of the RAS diminished tissue NF-B activation and upregulation of proinflammatory parameters. Ang II in vivo and in cultured cells activates NF-B and upregulates related genes. 1, 3 Although Ang II has been considered the effector peptide of the RAS, other peptides, such as the N-terminal, Ang III, and Ang IV, and the C-terminal, Ang(1-7), degradation products also possess biological activities. 8 However, their potential roles in pathophysiological processes are far from being completely understood. Ang III shares some Ang II functions, like blood pressure regulation, and participates in renal damage. 9, 10 Ang(1-7) induces vasodilatation and antiproliferation. 11 Ang IV [the Val(3)-Phe(8) fragment of Ang II] has sparked of great interest because of its wide range of physiological effects. Ang IV mediates important physiological functions in the central nervous system, including blood flow regulation and processes attributed to learning and memory. 12, 13 Ang IV participates in cell growth responses in cardiac fibroblasts, endothelial cells, and VSMCs. 14 -16 Interestingly, an antiapoptotic role for Ang IV in neuronal cells was reported. 17, 18 The existence of specific receptor subtypes for Ang peptides has been investigated. 19, 20 Two main subtypes, AT 1 and AT 2 that bind mainly to Ang II and Ang III, have been cloned and extensively studied. A different and specific receptor for Ang(1-7), the mas receptor, has recently been described. 11 Ang IV binds to a specific receptor, the AT 4 , that has recently been identified as insulin-regulated aminopeptidase (IRAP) by cross-linking to an Ang IV analogue, purifying the protein by chromatography and SDS-PAGE, and identifying tryptic peptides using mass spectrometry. 12 The presence of Ang IV-specific binding sites has been identified in various mammalian tissues and cells, including brain, blood vessels, heart, kidney, and cultured VSMCs. 16, 19, 20 In an endothelial model of balloon injury, Ang IV binding was increased in media, neointima, and reendothelialized cell layer, suggesting a role for Ang IV in vascular wall remodeling after damage. 21 Ang IV could contribute to vascular damage through the stimulation of cell growth and plasminogen activator inhibitor (PAI-1) expression. 22 Inflammation is a key event in the progression of atherosclerosis and hypertension. However, whether Ang IV possesses proinflammatory properties has not been investigated. Our aim was to investigate whether Ang IV could regulate proinflammatory mediators, evaluating the activation of NF-B pathway and proinflammatory NF-B-related genes in cultured VSMCs.
Materials and Methods

Materials
Ang peptides were obtained from BACHEM. Antibodies to NF-B subunits were from Santa Cruz; NF-B consensus (5Ј-AGT-TGAGGGGACTTTCCCAGGC-3Ј) and mutant (5Ј-AGTTGAGG-CTCCTTTCCCAGGC-3Ј) oligonucleotides were from Promega. ␣-[ 
Cell Cultures
Rat VSMCs were obtained from thoracic aorta of Wistar-Kyoto rats by collagenase method. 23 Murine VSMC were prepared from 2 different strains, AT 1 knockout mice (provided by Dr Sugaya, Tanabe Seiyaku Corp, Osaka, Japan) and their wild littermates. 24 For experiments, cells at 80% confluence from passages 2 to 5 were used.
Radioligand Binding and Enzyme Assay
In membranes, homogenates from rat VSMCs, prepared as described, binding experiments and determination of the cystinil aminopeptidase catalytic activity were done. 25 
NF-B Activation
Nuclear and cytosolic extracts were prepared by homogenization and centrifugation. 23 NF-B DNA binding activity was determined in nuclear extracts by binding with labeled NF-B consensus and electrophoresis. To quantify cytosolic IB␣ and phospho-IkB␣, Western blot analyses were done. 23 The quality of proteins and efficacy of protein transfer was evaluated by Red Ponceau staining (not shown). In all experiments, protein content was determined by the BCA method. For immunofluorescence, cells were fixed (3%PFA, 10 minutes and 0.1% Triton-X100, 1 minute) and incubated with antibodies against p50/p65 subunits and then with FITC-labeled secondary antibody. The absence of primary antibody was the negative control (not shown).
To study NF-B-dependent gene transcription, VSMCs were seeded in 6-well plates and 24 hours later cells were transient transfected with FUGENE (Roche Molecular Biochemicals) containing 1 g NF-B/luc promoter and 1 g TK-renilla as internal control (Clontech). After a 24-hour serum-starvation step, cells were stimulated for 24 hours, and luciferase/renilla activity was measured.
Gene and Protein Studies
Total RNA was isolated with Trizol and proinflammatory gene expression was analyzed by real-time PCR. 26 Assays on demand used were as follows: mice MCP-1, Mm00441242_m1; IL-6, Mm00446190_m1; TNF-␣, Mm00443258_m1; ICAM-1, Mm00516023_m1; PAI-1, Mm00435860_m1; and human IRAP, Hs00194378_m1. MCP-1 mRNA expression was also analyzed by Northern blot, 23 and MCP-1 release by ELISA (BD, Pharmingen). A cytokine/chemokine array kit (Ray Biotech, Inc) was used to detect a panel of 22 proteins in cell lysates from WT mice VSMCs.
Statistical Analysis
The autoradiographs were scanned using the GS-800 Calibrated Densitometer (Quantity One, Bio-Rad). Data of gene expression were normalized against those of the corresponding G3PDH. Results are expressed as n-fold increase over control as meanϮSEM of the experiments made. Significance was established with GraphPAD Instat using Student t test (GraphPAD Software), Wilcoxon and Student-Newman-Keuls text. Differences were considered significant when PϽ0.05.
Results
Ang IV Activates NF-B in Cultured Rat VSMCs
Ang IV increased NF-B DNA-binding activity after 15 minutes, peaked at 1 hour, and diminished to control levels by 6 hours ( Figure 1A ). This response was dose-dependent, and maximal after 1 hour with 10 Ϫ9 mol/L Ang IV ( Figure 1B ). Ang IV response was higher than Ang II and with longer kinetics, remaining elevated after 2 hours ( Figure 1A) .
By supershift assays, we have observed that antibodies to p50 and p65, but not c-Rel, shifted the band to a higher molecular weight, showing that Ang IV-activated NF-B complex is a p50/p65 heterodimer ( Figure 2A ). In control cells, a diffuse cytoplasmic immunofluorescence was seen with p50 or p65 antibodies. When cells were treated for 1 hour with 10 Ϫ9 mol/L Ang IV, an intense nuclear fluorescence was observed with both antibodies, showing nuclear translocation of NF-B ( Figure 2B ).
NF-B activation involves dissociation of IB and subsequent degradation. In control cells, IB␣ was found in cytosolic fraction as a protein of around 39 kDa (Western blot). After 1 hour of Ang IV stimulation, this band disappeared, indicating IB␣ degradation, and caused phosphorylation of IB␣ ( Figure 3A ). These effects were closely correlated with the time-course of Ang IV-induced NF-B activation and p50/p65 nuclear translocation. IB is degraded by 2 distinct pathways: I-kinase-dependent phosphorylation or calcium/calpain (calcium-activated neutral proteinase) process. 27 VSMCs were incubated with MG132 (proteasome inhibitor) or calpeptin (calpain inhibitor). Both inhibitors diminished IB␣ proteolysis, suggesting a parallel contribution of both pathways. MG132 treatment, but not calpeptin, increased IB␣ phosphorylation ( Figure 3B ). Calpain inhibitors can block proteolysis of IB␣ and NF-B activation, while having no effect on the signal-induced phosphorylation of the inhibitor, as we have observed. 28 
Ang IV Activates NF-B Pathway via AT 4 Receptor
We investigated the receptor subtype involved in NF-B pathway. Cells were preincubated with specific AT-R antagonists (Losartan for AT 1 , PD123319 for AT 2 , and divalinal for AT 4 19,20 ) and then stimulated with Ang II or Ang IV for 1 hour.
In rat VSMCs, both AT 1 or AT 2 antagonists partially blocked Ang II-induced NF-B DNA-binding activity, whereas when both antagonists were added together NF-B activation was completely abolished. In contrast, neither AT 1 nor AT 2 antagonists diminished Ang IV-induced NF-B Ϫ9 mol/L Ang IV or 10 Ϫ7 mol/L Ang II for 1 hour and immunofluorescence using p50 and p65 antibodies was done.
activation ( Figure 4A ). Similar results were observed in VSMCs from WT mice ( Figure 4B ). In VSMCs from AT 1 knockout mice, Ang IV increased NF-B DNA-binding activity ( Figure 4C ), which was not blocked by the AT 2 antagonist, showing that Ang IV acts independently of AT 1 and AT 2 receptors.
We have investigated the presence of AT 4 /IRAP receptors in VSMCs. Ang IV-specific binding sites, antagonized by divalinal, have previously described in cultured bovine VSMCs. 16 rosine kinases (PTK). 19, 20 We showed that AT 1 /NF-B pathway is mediated by PTK, but not PKC, activation, whereas AT 2 /NF-B is PTK and PKC independent. 23 We investigated whether these intracellular signals are involved in AT 4 /NF-B pathway. Treatment with several PKC inhibitors did not modify NF-B activation induced by Ang IV (figure 5), suggesting that PKC is not involved in this process. The PTK inhibitors, genistein, erbstatin, and herbimycin A, caused a marked reduction in Ang IV-induced NF-B activation ( Figure 5 ). These data suggest that AT 4 /NF-B pathway is mediated by activation of tyrosine phosphorylation.
Effect of Ang IV on NF-B-Mediated Gene Transcription
We have investigated whether Ang IV regulates NF-Bmediated gene expression by transient transfection with a luciferase reporter plasmid (NF-B/luc). In mice VSMCs, Ang IV potently increased NF-B promoter activity ( Figure  6 ), as observed with Ang II, IL-1␤, and TNF-␣. In AT 1 knockout VSMCs, Ang IV also increases NF-B-mediated gene expression. The AT 4 antagonist divalinal significantly diminished Ang IV-induced luciferase activity, showing that NF-B promoter activation was mediated by AT 4 receptors.
We have investigated whether Ang IV regulates some proinflammatory factors under NF-B control. By real-time PCR, we have found that in AT 1 knockout VSMC Ang IV upregulated gene expression of the adhesion molecule ICAM-1, the cytokines IL-6 and TNF-␣, the chemokine MCP-1, and the prothrombotic factor PAI-1 ( Figure 7A ). The AT 4 antagonist significantly diminished Ang IV-mediated gene overexpression (PϽ0.05). Using a protein cytokine array system a correlation between increasing levels of certain cytokines and chemokines with the Ang IV-increased gene overexpression were found ( Figure 7B ). We have further investigated whether NF-B regulates Ang IV-induced proinflammatory gene expression, studying MCP-1 gene, an important mediator of monocyte infiltration. 30 In rat VSMCs, Ang IV stimulation rapidly increased MCP-1 mRNA levels after 30 minutes, being maximal at 3 hours ( Figure 8A ). Similar results were found in VSMCs from WT mice (not shown). Ang IV increased MCP-1 protein production, as shown in conditioned media from Ang IVtreated mice VSMC ( Figure 8B ). Some works have demonstrated that, in VSMCs, Ang II increases MCP-1 via AT 1 receptors. 23, 31 In VSMCs from AT 1 knockout mice, Ang IV increases MCP-1 gene ( Figure 8C ) and protein release (not shown). The AT 4 antagonist completely abolished Ang IVinduced MCP-1 gene upregulation, clearly indicating AT 4 receptors are involved in this process. We have blocked NF-B pathway using the following NF-B inhibitors: pyrrolidine dithiocarbamate (PDTC, an NF-B inhibitor with antioxidant properties as a thiol agent), MG132 (a proteasome inhibitor of IB degradation), gliotoxin (an immunosuppressor), and parthenolide (a specific inhibitor of the IKK/NF-B pathway, which inhibits IKK activity, enhances stability of IB␣, and blocks nuclear translocation of NF-B). Pretreat- 
Discussion
We have demonstrated for the first time that Ang IV activates the transcription factor NF-B and upregulates related genes involved in cardiovascular damage, such as the adhesion molecule ICAM-1, the cytokines IL-6 and TNF-␣, the chemokine MCP-1, and the prothrombotic factor PAI-1. The Ang IV response is mediated by activation of AT 4 receptors, independently of AT 1 and AT 2 receptors. These results reveal novel concepts of RAS in the cardiovascular system, suggesting that Ang IV, via AT 4 receptors, could play an active role in the inflammatory process associated with vascular damage.
NF-B regulates many genes that play key roles in the inflammatory process. 3, 4 We have observed that in cultured VSMCs, Ang IV increased NF-B DNA-binding activity, which is functional in its ability to transactivate B containing promoters, and caused nuclear translocation of p50/p65 heterodimer and degradation of cytosolic IB␣, mediated by I-kinase-dependent phosphorylation and calpain pathways. NF-B inhibitors ameliorate end-organ damage in models characterized by activated tissue RAS. 3, 4, 26 We have observed that NF-B inhibitors diminished Ang IV-induced gene overexpression (exemplified by MCP-1), showing a NF-Bmediated transcriptional mechanism. The AT 4 antagonist blocked Ang IV-induced NF-B activation and markedly inhibited NF-B-mediated gene transcription (transfection of NF-B/luc reporter) and mRNA overexpression of ICAM-1, IL-6, TNF-␣, MCP-1, and PAI-1, revealing that NF-B pathway activation and upregulation of NF-B-related genes are mediated by AT 4 receptors. In vascular diseases, ACE inhibition diminishes local NF-B activation and proinflammatory parameters. 30, 31 The beneficial effects of ACE inhibition could be due not only to the blockade of Ang II generation but also to the formation of Ang degradation products, such as Ang IV, 32, 33 and thereby inhibiting NF-B activation (and upregulation of proinflammatory genes) induced by this peptide.
A common feature of all stages of atherosclerosis is inflammation of the vessel wall. The involvement of RAS in the pathogenesis of human atherosclerosis has already been demonstrated. RAS blockade diminished the presence of inflammatory cells and proinflammatory parameters in the lesion, serum, and circulating monocytes. 3, 30, 31 In human atherosclerotic plaques, the monocytes/macrophages presented high ACE activity associated with elevated levels of proinflammatory cytokines, such as IL-6. 34, 35 In the atheroma plaques, there is an elevated production of Ang II and activation of proteases (mainly by activated macrophages) than can generate Ang degradation products, including Ang IV. Other evidences suggest that Ang IV could contribute to vascular damage. In a model of balloon injury, Ang IV binding in the lesion was increased, mainly in VSMCs and endothelial cells. 21 ACE is expressed at the shoulder region of atherosclerotic plaques, and ACE activity is enhanced in unstable plaques; therefore, Ang peptides may participate in the plaque instability. Thus, in VSMCs, Ang IV, via AT 4 activation, caused gene overexpression of ICAM-1, IL-6, TNF-␣, MCP-1, and PAI-1, and could contribute to the progression and rupture of the plaque by activation of inflammation and thrombosis.
The inflammatory process is also important in the development of vascular damage in hypertension. Activation of leukocytes and monocytes was found in patients with essential hypertension, presenting elevated adherence to endothelial cells and producing higher levels of cytokines, IL-1␤, TNF-␣, and TGF-␤ on stimulation. 2, 3, 36 In experimental models of hypertension, such as SHR, Ang II infusion and double-transgenic rats for renin and angiotensinogen, monocyte/macrophage infiltration, and overexpression of proinflammatory parameters into the vessel wall, heart, kidney, and brain have been described. ACE inhibitors decrease both inflammatory factors and monocyte/macrophage infiltration. 31 Many studies have clearly demonstrated that Ang II, by direct activation of immune cells or by production of inflammatory mediators, contributes to tissue damage in hypertension. Our data disclose that the Ang degradation product Ang IV also activates proinflammatory parameters, enlarging the contribution of RAS activation in the pathogenesis of hypertension.
AT 1 and AT 2 are 7 transmembrane-spanning G proteincoupled receptors and elicit different intracellular signaling, although both receptors share a common molecular pathway: the activation of NF-B. 1,3,23 AT 1 receptor, similar to classical cytokines, activates protein kinases, such as PKC, PTK, phosphatidylinositol 3 kinase (PI3K), Akt, focal adhesion kinases (FAK), and mitogen-activated protein kinases (MAPK), among other signals. AT 2 receptor activates protein phosphatases, kinin/NO/cGMP system, and production of ceramides. 1, 19, 20 Recently, AT 4 binding sites have been characterized as being insulin-regulated aminopeptidase and can therefore be denoted as AT 4 /IRAP. IRAP is also known as oxytocinase (OTase) or placental leucine aminopeptidase (P-LAP). 12 These different denominations are related to its independent "discovery" by several research teams and related to its enzymatic properties. AT 4 /IRAP is a type II integral membrane protein and a member of the M1 family of zinc-dependent metallopeptidases. Some data indicate that after homodimer formation, IRAP can act as a classical receptor, transferring extracellular information across the cell membrane. These observations therefore may lead to the classification of this protein as a mixed enzyme/receptor. In addition or alternatively, Ang IV can exert its effects by inhibiting the catalytic activity of IRAP, 12, 13 possibly through an allosteric mechanism. 37 As a consequence, Ang IV could reduce the cleavage of some central peptides, an effect of paramount importance in brain physiology. By this mechanism, Ang IV may extend the half-life of endogenous neuropeptides that increase memory. 38 The AT 4 antagonist divalinal was designed by Harding's laboratory, 39 and binds only to AT 4 , but not AT 1 or AT 2 receptors, with high affinity to a similar number of binding sites as [
125 I]-Ang IV. Divalinal is an antagonist of Ang IV-mediated actions in a variety of physiological systems, 39 -41 as we have observed in Ang IV-induced NF-B activation in VSMCs, although some authors have found agonistic properties in other systems. 40 AT 4 /IRAP binds with high affinity to the Ang IV analogue, 12 Ang IV-specific binding sites, antagonized by divalinal, have been described in VSMCs. 16,19 -21 In line with these observations, we found in the present study that in these cells there is gene expression of IRAP and, in cellular membranes, specific binding to [
125 I]-Ang IV and IRAP enzymatic activity. These data confirm that AT 4 /IRAP is also expressed in VSMCs used in this study.
Although, as outlined earlier, the intracellular signaling of AT4/IRAP is not completely established, Ang IV is described to mediate a number of effects via this enzyme/receptor. Early works demonstrated that Ang IV is a vasodilator in kidney and brain. 42, 43 Ang IV activates several protein kinases. 44, 45 In endothelial cells, Ang IV increases PI3K, PI-dependent kinase-1 (PDK-1), extracellular signal-related kinases (ERK1/2), protein kinase B-␣/Akt (PKB-␣), and p70 ribosomal S6 kinase (p70S6K) activities. 46 Endotheliumdependent vasodilation is mediated by NO and cGMP production, 30 intracellular calcium release, and activation phospholipase C and PI3K. 29 In rat aorta, PTK inhibition and membrane L-type Ca 2ϩ channels blockade diminished Ang IV contractile effects. 44 In tubular cells, Ang IV increases tyrosine phosphorylation of the focal adhesion-associated proteins, p125-FAK and paxillin. However, Ang IV does not affect cAMP or cGMP production and does not increase cytosolic calcium concentrations. 45 These data suggest differences in Ang IV signaling depending on the cell type, suggesting that future studies are needed to clearly define Ang IV intracellular mechanisms. Whereas AT 1 and AT 2 receptors present some well-established features of relevance to health and disease, 19, 20 the existence of separate receptors for Ang fragments offers exciting possibilities for new therapeutics to target the diverse actions of these peptides.
Our data afford a novel intracellular mechanism involved in Ang IV signaling in VSMCs: the activation of the NF-B pathway. We have also observed that PTK inhibitors diminished Ang IV-induced NF-B activation, showing that tyrosine phosphorylation mediates this process.
In summary, our results demonstrate that, in cultured VSMCs, Ang IV via AT 4 receptors activates the NF-B pathway and upregulates several genes as ICAM-1, IL-6, TNF-␣, MCP-1, and PAI-1. Although Ang II has long been considered to represent the end product of RAS, there is accumulating evidence showing additional effector peptides with diverse functions. Many works support the importance of Ang IV in the fields of cognition, cardiovascular, and renal metabolism and pathophysiological conditions such as diabetes, atherosclerosis, and hypertension. Our data suggest that Ang IV could contribute to inflammatory events in cardiovascular diseases via NF-B pathway and the regulation of proinflammatory genes.
